As a valued subscriber to the wealth of resources published by Relias Media, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
Using a population-based database, investigators found that the rate of readmission within 30 days following hospitalization for S. aureus bacteremia was high (22%) and resulted in high cost to the healthcare system.
The combination of oral vancomycin and intravenous metronidazole is not superior to vancomycin alone in the treatment of fulminant infection due to Clostridioides difficile.
Cefazolin (CZ) and ertapenem combination therapy was successfully used to salvage 11 cases of persistent methicillin-susceptible Staphylococcus aureus bacteremia. Modest in vitro synergy between CZ and ertapenem was demonstrated on testing of six clinical isolates, but in vivo activity appeared more potent in an animal model than as predicted by in vitro activity.
Chronic disabling fatigue affects up to 2% of adolescents and often follows Epstein-Barr virus-related mononucleosis. No clinically significant infectious, immune, neuroendocrine, or autonomic biomarker or pathophysiologic mechanism has been identified to differentiate those with mononucleosis who go on to develop chronic fatigue from those who recover.
We're overhauling our webinar series and would love your input on what is important to YOU! Take our five-minute survey and choose to be entered for a chance to win a $100 gift card. Just click the link below to start the survey.
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Updates Author Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jason Schneider, and Editorial Group Manager Leslie Coplin report no financial relationships to this field of study.
